The Daily Differential — Thursday, July 16, 2026

ACS Special Considerations

ACS is frequently painless, electrically subtle, or complicated by bleeding risk, renal disease, heart failure, or cardiogenic shock. Missing the atypical or high-risk patient delays reperfusion; applying a protocol blindly can worsen ischemia or precipitate collapse.

By the Blue Fish Med Desk Jul 16, 2026 · Phoenix

0:00 / –:–– AI‑generated audio

A 72-year-old woman sits forward on the stretcher, one hand pressed to her upper abdomen and the other gripping a cool emesis bag. Her daughter says the discomfort began while she was folding laundry, but the patient insists it is “indigestion,” not pain. She is pale, mildly breathless, and repeatedly asks whether she can go home. The ECG is being printed now, while the next decision remains unsettled.

— What’s your move? Read on.

Before you read

When do antiplatelet, anticoagulant, and reperfusion decisions change?
Which “routine” ACS treatments can harm this patient?

When to Think of It

Enter ACS when there is pressure, dyspnea, diaphoresis, nausea, syncope, unexplained weakness, epigastric discomfort, or new heart failure—especially in older adults, women, patients with diabetes, CKD, or prior CAD. Obtain and interpret a 12-lead ECG within 10 minutes; repeat it for ongoing symptoms or dynamic change. Consider posterior leads V7–V9 for horizontal ST depression in V1–V3 and right-sided leads, especially V4R, with inferior STEMI or suspected RV infarction.

Sick or Not Sick

The decisive fork is STEMI/occlusion MI or hemodynamic instability versus non-occlusive, stable ACS. Shock, malignant arrhythmia, acute pulmonary edema, refractory pain, dynamic ST changes, or posterior/right ventricular involvement require immediate cardiology/cath-lab escalation—not a prolonged “rule-out” pathway.

The First Fifteen Minutes

Suspected ACS without active bleeding → aspirin 324 mg PO, chewed, because irreversible platelet inhibition reduces coronary thrombus propagation.
Confirmed or strongly suspected NSTE-ACS/STEMI headed for PCI → unfractionated heparin 60 units/kg IV bolus, maximum 4,000 units, then 12 units/kg/h infusion, maximum 1,000 units/h, titrated to institutional aPTT/anti-Xa protocol; it limits thrombin generation while definitive therapy is arranged. Dosing varies by pathway and fibrinolysis strategy—check institutional protocol.
PCI strategy when cardiology recommends P2Y12 loading → ticagrelor 180 mg PO or clopidogrel 600 mg PO; these inhibit ADP-mediated platelet activation. Do not delay emergent cath for routine oral loading if anatomy or surgery is uncertain; follow the receiving interventional protocol.
Ongoing ischemic pain with SBP ≥90 mmHg, no RV infarction, severe aortic stenosis, or recent PDE-5 inhibitor → nitroglycerin 0.4 mg SL every 5 minutes for up to 3 doses, because venodilation lowers preload and myocardial oxygen demand. Avoid if hypotension, suspected RV infarction, or sildenafil/vardenafil within 24 hours or tadalafil within 48 hours.
Severe pain despite appropriate ischemic management and stable hemodynamics → fentanyl 25–50 mcg IV, cautiously repeated, because analgesia reduces distress but opioids may delay P2Y12 absorption and obscure deterioration.
ACS with pulmonary edema/hypoxemia → oxygen only if SpO₂ <90% or respiratory distress, targeting approximately 90–96%; routine oxygen in normoxia has no established benefit and may be harmful.
Suspected STEMI/occlusion MI → activate the cath lab immediately; fibrinolytic medication is not a default ED drug and requires cardiology/receiving-protocol selection, contraindication review, and weight-based dosing verification.

Definitive Care & Disposition

STEMI or suspected occlusion MI requires immediate PCI when timely; fibrinolysis is considered when PCI cannot be delivered within the accepted system target and no contraindication exists, followed by transfer for rescue/pharmaco-invasive care. NSTE-ACS receives telemetry, serial ECG/troponin testing, echocardiography as indicated, and early invasive management for high-risk features. Add high-intensity statin therapy—atorvastatin 80 mg PO—once ACS is established or strongly suspected, unless contraindicated. Admit all confirmed ACS; unstable patients require resuscitation-capable/ICU care.

How This One Kills

The lethal error is treating a nondiagnostic initial ECG and a negative first troponin as reassurance in a patient with ongoing ischemic symptoms—particularly missing posterior MI, left-main/proximal LAD ischemia, or spontaneous coronary artery dissection.

The Differential — What Else Looks Like This

Aortic dissection — pulse/BP differential, tearing pain, neurologic deficit, or mediastinal widening; antithrombotics can worsen hemorrhage.
Pulmonary embolism — pleuritic pain, hypoxemia, RV strain, or provoking risk; cath-lab activation may delay anticoagulation and definitive imaging.
Stress cardiomyopathy — post-stressor presentation with diffuse or nonterritorial dysfunction; premature assumptions about coronary anatomy can misdirect care.
Esophageal rupture — forceful vomiting, toxic appearance, subcutaneous emphysema; antiplatelet/anticoagulant therapy can compound bleeding.

The Second-Day Story

Older adults and patients with diabetes or CKD may have dyspnea, nausea, weakness, confusion, syncope, or isolated diaphoresis rather than chest pain. Baseline ECG abnormalities and chronically elevated troponin further degrade the signal. The diagnosis rests on trajectory: symptoms, serial ECGs, delta troponin, bedside ventricular-wall-motion assessment, and a low threshold for cardiology input when the clinical story remains concerning.

Back to Our Patient

Back to our 72-year-old woman with “indigestion”: her repeat history reveals exertional onset, diaphoresis, and persistent discomfort; the ECG shows horizontal ST depression in V1–V3 with posterior ST elevation on V7–V9. She is recognized as a likely posterior occlusion MI, not a benign gastrointestinal complaint. She is pale but awake with SBP 118 mmHg, clear lungs, and no evidence of RV infarction or dissection, so she is not yet in shock; aspirin is chewed, heparin and cardiology-directed P2Y12 loading are given, nitroglycerin is used cautiously for persistent pain, and the cath lab is activated. She proceeds directly to emergent PCI and is admitted to the cardiac ICU.

Patient Presentation to Attending

How you’d present this patient on the floor — tight, pertinent positives and negatives, no rambling

“72-year-old woman with diabetes and known CAD presents with 45 minutes of exertional epigastric pressure, diaphoresis, nausea, and dyspnea, without pleuritic pain, tearing radiation, syncope, or focal neurologic symptoms. She remains uncomfortable, is pale and mildly tachypneic, with BP 118/70, symmetric pulses, clear lungs, and no focal neurologic deficit. Initial ECG showed horizontal ST depression in V1–V3, and repeat posterior leads show ST elevation; initial troponin is pending. This is posterior occlusion MI until proven otherwise, without current shock or clear dissection features. I have given chewed aspirin, will initiate protocol-directed anticoagulation and P2Y12 therapy, avoid routine oxygen and nitrates if RV involvement or hypotension develops, and activate the cath lab for immediate PCI.”

Study Directive

Draw the 15-lead ECG layout from memory and practice identifying posterior and RV infarction patterns. Review your local STEMI/NSTE-ACS pathway, including heparin and P2Y12 options. Complete five cases distinguishing ACS from dissection, PE, and esophageal rupture, and state the immediate contraindication to nitrates in each.

Recent Literature

Review or guideline 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Rao SV, O'Donoghue ML, Ruel M, et al. · Circulation, 2025 · PMID 40014670 · cited 492×

Use this multidisciplinary guideline for current ED management of ACS, including antithrombotic therapy, invasive strategy, cardiogenic shock, and special patient populations.

4 of 5

The Hypotensive Post-Cardiac Arrest Patient

Post-arrest hypotension is common and independently associated with secondary brain and myocardial injury. ROSC is not the endpoint: inadequate coronary,...

Listen: EM:RAP podcast →

0:00 / –:–– AI‑generated audio

The Case

A 63-year-old man lies motionless beneath warming blankets, his skin gray and damp after a witnessed collapse at home. The monitor now shows a narrow rhythm and a pulse, but the arterial pressure cycles at 68/42 mmHg. His wife stands at the doorway clutching the phone that summoned help, while the team must decide whether the heart has truly recovered—or only restarted.

Before You Read

What blood-pressure and perfusion target should guide post-ROSC care?
Which shock phenotype is present, and when should vasopressors, fluids, or inotropes be used?
Which reversible causes still need immediate treatment after ROSC?

Why It Matters

Post-arrest hypotension is common and independently associated with secondary brain and myocardial injury. ROSC is not the endpoint: inadequate coronary, cerebral, and systemic perfusion can rapidly lead to recurrent arrest or devastating neurologic outcome.

When to Think of It

Identify hypotension after ROSC by MAP <65 mmHg, SBP <90 mmHg, falling ETCO₂, cool extremities, altered mental status, oliguria, rising lactate, or poor arterial waveform. Assume mixed shock until proven otherwise: myocardial stunning, acute coronary occlusion, hypovolemia, vasodilation, obstructive shock, and dysrhythmia may coexist.

Sick or Not Sick

The critical call is persistent hypoperfusion despite initial support—post-arrest shock requiring vasopressor/inotrope and ICU-level care. Recurrent instability, STEMI/occlusion MI, severe LV/RV dysfunction, lactate elevation, or escalating pressor needs warrants early critical care, cardiology, and possibly mechanical-circulatory-support consultation.

The First Fifteen Minutes

Confirm a reliable pressure, obtain large-bore IV/IO access, and place an arterial line when feasible; inaccurate cuff readings can drive harmful overtreatment.
MAP <65 or SBP <90 after a cautious assessment for hemorrhage/volume loss → norepinephrine 0.05–0.1 mcg/kg/min IV infusion, titrated to MAP ≥65 mmHg, because α1 vasoconstriction restores coronary and cerebral perfusion. Titrate to the lowest effective dose.
Suspected hypovolemia or hemorrhage with no pulmonary edema → 500–1,000 mL isotonic crystalloid IV, reassessing dynamically, because preload restoration may improve stroke volume; avoid indiscriminate liters in myocardial failure.
Persistent low output with adequate MAP and severe LV dysfunction → dobutamine 2–5 mcg/kg/min IV infusion, because β1 stimulation improves contractility; it may worsen tachyarrhythmias and ischemia, so use ICU monitoring.
Hypoxemia after ROSC → ventilate with 100% oxygen initially, then titrate to SpO₂ 92–98% once reliable measurement is available, because both hypoxemia and prolonged hyperoxia can injure the post-arrest brain.
Comatose patient not following commands → initiate a protocolized temperature-control strategy, commonly targeting 32–37.5°C, because prevention of fever and controlled temperature reduce secondary neurologic injury. Exact target and duration vary by institutional protocol.
Seizure after ROSC → midazolam 5 mg IV/IM, repeat once if needed, or lorazepam 0.1 mg/kg IV, maximum 4 mg, because benzodiazepines suppress active seizure activity; secure the airway and obtain EEG/neurology input.

Definitive Care & Disposition

Perform a 12-lead ECG immediately and repeat it if nondiagnostic with ongoing concern. Activate emergent coronary angiography for STEMI, ongoing ischemia, recurrent ventricular arrhythmia, or shock strongly suspected to be coronary; routine immediate angiography is individualized in patients without these features. Evaluate bedside echo, electrolytes, glucose, temperature, toxicologic and infectious causes, tamponade, PE, pneumothorax, and hemorrhage. Admit to an ICU capable of ventilatory, hemodynamic, temperature, EEG, and post-arrest neuroprognostication care.

How This One Kills

The lethal failure is accepting a palpable pulse as adequate ROSC while MAP remains low, then delaying vasopressor support and coronary evaluation. Secondary brain ischemia and recurrent arrest can develop even when the monitor looks organized.

The Atypical Presentation

Post-arrest patients are sedated, ventilated, hypothermic, and unable to report symptoms, so shock may appear only as hypotension, low urine output, mottling, rising lactate, or poor ETCO₂. A normal initial ECG does not exclude transient coronary occlusion or stunning. Serial hemodynamics, bedside echocardiography, lactate trend, urine output, capnography, and repeat examinations are more useful than a single “successful” pulse check.

Back to Our Patient

Back to our 63-year-old man: ROSC is confirmed, but MAP is approximately 51 mmHg with cool skin and poor urine output, so he has post-cardiac-arrest shock rather than stable recovery. Ventilation and oxygen are controlled, a reliable pressure is obtained, and norepinephrine is started and titrated toward MAP ≥65; ultrasound shows depressed LV function without tamponade or a tension pneumothorax, so only a cautious fluid challenge is given. The ECG shows anterior ST elevation, prompting emergent coronary angiography, while temperature control and ICU post-arrest care begin. He is transferred intubated to the cardiac ICU on norepinephrine for PCI and ongoing neurologic and hemodynamic management.

Patient Presentation to Attending

“63-year-old man had a witnessed out-of-hospital cardiac arrest with ROSC after defibrillation and CPR, but remains comatose and hypotensive at 68/42. He is intubated, has a weak pulse, cool mottled skin, low urine output, and a low but present ETCO₂; bedside echo shows depressed LV function without tamponade or a dilated RV. His ECG now demonstrates anterior ST elevation. This is post-arrest myocardial stunning with suspected acute coronary occlusion causing cardiogenic shock. I will titrate norepinephrine to MAP at least 65, avoid excessive fluids, pursue emergent coronary angiography, initiate protocolized temperature control, and admit him to the cardiac ICU.”

Study Directive

Create a post-ROSC checklist covering airway, oxygen/ventilation, MAP, ECG, glucose, temperature, seizure detection, echo, and reversible causes. Practice classifying five shock cases as LV, RV/obstructive, distributive, or hypovolemic. Review your local coronary angiography and temperature-control pathways, then verbally present one post-arrest patient in under 60 seconds.

---

Key Medications

Norepinephrine: 0.05–0.1 mcg/kg/min IV, titrate to MAP ≥65 mmHg.
Crystalloid: 500–1,000 mL IV bolus, reassess; smaller boluses may be preferable with LV failure.
Dobutamine: 2–5 mcg/kg/min IV, titrate in ICU.
Midazolam for seizure: 5 mg IV/IM, may repeat once; lorazepam 0.1 mg/kg IV, max 4 mg. Verify local seizure protocol.
Hydrocortisone is not routine for post-arrest shock; if refractory shock suggests adrenal insufficiency, 100 mg IV, then specialist/ICU-directed dosing may be used.
Pediatric post-ROSC vasopressor and fluid therapy is weight-based and age-specific; use PALS/institutional protocol.

High-Yield Pearls

Post-ROSC hypotension is a treatment target even when a pulse and organized ECG are present; cerebral perfusion remains pressure-dependent.
A falling ETCO₂ after ROSC may signal recurrent arrest, tube/circuit failure, or worsening perfusion—do not simply increase the pressor.
Echo phenotype matters: LV failure favors inotropy/pressors; RV dilation should redirect the search toward PE, hypoxia, or excessive airway pressure.

The Mimics

Recurrent arrest/PEA — loss of arterial waveform, ETCO₂ drop, or absent pulse; treating it as ordinary hypotension delays CPR.
Tension pneumothorax — unilateral breath sounds, rising airway pressures, obstructive physiology; pressors alone cannot fix the obstruction.
Massive PE — RV dilation/strain and persistent shock; missing it delays thrombolysis or embolectomy consideration.
Hemorrhage/hypovolemia — falling hemoglobin, bleeding source, small/hyperdynamic ventricles; escalating vasoconstriction without volume/blood worsens tissue perfusion.

Board Question

A comatose patient has ROSC after VF arrest but remains at 70/40 mmHg with cool extremities and depressed LV function. Which initial vasoactive strategy is most appropriate?

ADopamine as first-line therapy
BNorepinephrine infusion titrated to MAP ≥65 mmHg
CHigh-dose nitroglycerin infusion
DImmediate large-volume crystalloid, regardless of lung findings

Reveal answer

Correct: B

Norepinephrine infusion titrated to MAP ≥65 mmHg. Norepinephrine is generally preferred for post-arrest hypotension because it restores vascular tone with less tachyarrhythmia than dopamine. Fluids should be selective, and nitroglycerin is contraindicated in significant hypotension.

Recent Literature

Review or guideline Blood pressure targets and management during post-cardiac arrest care
Resuscitation, 2023 · cited 20×

Provides a practical synthesis of post-ROSC blood-pressure targets, monitoring, fluids, and vasopressor use for treating hypotension while avoiding excessive afterload.

Full text · open access
Recent clinical Blood Pressure and Oxygen Targets on Kidney Injury After Cardiac Arrest
Circulation, 2023 · cited 12×

This randomized trial found that targeting a higher versus lower mean arterial pressure after cardiac arrest did not reduce acute kidney injury, arguing against routinely escalating pressure solely for renal protection.

TheDaily Differential

ACS Special Considerations

When to Think of It

Sick or Not Sick

The First Fifteen Minutes

Definitive Care & Disposition

How This One Kills

The Second-Day Story

Study Directive

Recent Literature

More in Today's Issue

Guidelines on Heart Failure Management

Pulse Checks

The Hypotensive Post-Cardiac Arrest Patient

Hemodynamic Management of Massive Pulmonary Embolism

Yesterday’s Differential

Journal Watch

Shift Pearls: Anticoagulation with Heparin in PE

Dulcor

Podcast Picks

High-Flow or Standard O2 for Hypoxemic Respiratory Failure?

EMA 2026 June

Critical Care Corner

Heart Failure Literature Summaries

Pharmacology Corner

Ertapenem

Furosemide

ECG of the Day

Case of the Day